Imaging Test for Metastatic Urothelial and Breast C cancers and NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early phase, first-in-human imaging study evaluates the feasibility, distribution in the body, and dosimetry of an imaging agent in adults with metastatic urothelial carcinoma, HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or non–small cell lung cancer. Participants receive the imaging agent and undergo imaging procedures to measure uptake and exposure. The study is conducted at selected research facilities and is sponsored by RayzeBio, with sites in Australia. Eligibility includes adults with biopsy-confirmed metastatic disease and nonpregnant status for those who could become pregnant, with site-specific inclusion criteria to be reviewed at enrollment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Are at least 18 years old at the time of signing the informed consent form (ICF)
* Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC

Exclusion Criteria:

* For Women of Childbearing Potential: Are pregnant or breastfeeding

Note: Additional criteria may apply and will be assessed by the study site

Where it's running

• Research Facility
  St Leonards, New South Wales, Australia Recruiting
• Research Facility
  Nedlands, Australia Recruiting
• Research Facility
  Perth, Australia Recruiting
• Research Facility
  Christchurch, New Zealand Recruiting
• Research Facility
  Johannesburg, South Africa Active not recruiting
• Research Facility
  Pretoria, South Africa Active not recruiting

Study contacts

• Study coordinator: RayzeBio Clinical Trials
• Email: clinicaltrials@rayzebio.com
• Phone: (619) 657-0057

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using blood-based tumor DNA (ctDNA) to find leftover breast cancer after treatment

  This research will test whether a simple blood test that looks for tiny bits of tumor DNA can tell if people treated for breast cancer (including HR+/HER2-, HER2+, and triple-negative) still have leftover cancer or are at risk of recurrence.

  Recruiting at 16 sites Tempus AI · Birmingham, Alabama and 15 other locations · NCT07211178

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Testing TUB-030 for advanced solid tumors

  This study is testing a new drug called TUB-030 to see if it can safely help adults with advanced solid tumors, especially those with head and neck cancer or non-small cell lung cancer.

  Recruiting at 19 sites Phase 1/2 Gilead Sciences · New Haven, Connecticut and 19 other locations · NCT06657222

• Milaberon for treating advanced solid tumors

  This study is testing if a higher dose of mirabegron can help people with advanced solid tumors feel better while keeping an eye on any side effects.

  Recruiting Phase 2 Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT06534762

• Single‑fraction versus multiple‑fraction SBRT for treating limited metastases (SPRINT)

  This trial will test whether a single high‑dose SBRT treatment works as safely and effectively as multiple smaller SBRT treatments for people with limited metastases from breast, prostate, lung, or colorectal cancer.

  Recruiting at 2 sites European Organisation for Research and Treatment of Cancer - EORTC · Aalst and 14 other locations · NCT06462963

• Using advanced mammography techniques to assess breast cancer treatment response

  This study is testing two new mammography techniques to see if they can better predict how well chemotherapy is working for people with locally advanced breast cancer.

  Recruiting Early Phase 1 Stony Brook University · Stony Brook, New York · NCT06220214

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.